Rubella

Summary

Rubella (MONDO:0004656) is a disease and 69 clinical trials. Top therapeutic interventions include rubella virus vaccine live. A subtype of primary viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 69

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	rubella
Mondo ID	MONDO:0004656
EFO	EFO:1002026
MeSH	D012409
DOID	DOID:8781
ICD-10-CM	B06
ICD-11	410022648
NCIT	C85051
SNOMED CT	36653000
UMLS	C0035920
MedGen	48514
GARD	0004742
Is cancer (heuristic)	no

Also known as: german measles · Rubella infection · Rubella virus caused disease or disorder · Rubella virus disease or disorder · Rubella virus infectious disease · three day measles · three-Day Measles

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › rubella

Related subtypes (31): plantar wart, monkeypox, smallpox, human papilloma virus infection, Rotavirus infection, Arenaviridae infectious disease, Astroviridae infectious disease, Caliciviridae infectious disease, cowpox, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Herpesviridae infectious disease, influenza, Mononegavirales infectious disease, Nidovirales infectious disease, phlebotomus fever, Picornaviridae infectious disease, polyomavirus infectious disease, Togaviridae infectious disease, viral encephalitis, viral hepatitis, viral pneumonia, viral exanthem, deltaretrovirus infections, Bunyaviridae infectious disease, viral sexually transmitted disease, lentivirus infection, viral myocarditis, viral pericarditis, adenoviridae infectious disease, aleutian mink disease, human

Subtypes (1): congenital rubella syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Rubella Virus, Live Attenuated	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 69.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	31
PHASE4	14
Not specified	12
PHASE2	7
PHASE2/PHASE3	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00126997	PHASE4	COMPLETED	Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00313950	PHASE4	COMPLETED	Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
NCT00326183	PHASE4	COMPLETED	Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
NCT00388440	PHASE4	COMPLETED	Assess GSK Biologicals’ MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
NCT00432731	PHASE4	COMPLETED	Safety Study of a Refrigerator-stable Formulation of VARIVAX®
NCT01777529	PHASE4	COMPLETED	Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
NCT02325310	PHASE4	COMPLETED	Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
NCT02643433	PHASE4	COMPLETED	Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines
NCT02880865	PHASE4	COMPLETED	Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
NCT03071575	PHASE4	COMPLETED	Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
NCT03160820	PHASE4	COMPLETED	Study on Immunization Schedule of Beijing Tiantan Biological’s Measles-mumps-rubella(MMR) Vaccine
NCT05279248	PHASE4	UNKNOWN	The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
NCT05952505	PHASE4	UNKNOWN	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
NCT06331702	PHASE4	COMPLETED	Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
NCT06815835	PHASE3	NOT_YET_RECRUITING	Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
NCT00092391	PHASE3	COMPLETED	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
NCT00092430	PHASE3	COMPLETED	Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
NCT00109343	PHASE3	COMPLETED	V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
NCT00127010	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00127023	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00351923	PHASE3	COMPLETED	Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
NCT00384397	PHASE3	COMPLETED	A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT00402831	PHASE3	COMPLETED	ProQuad® Intramuscular vs Subcutaneous
NCT00406211	PHASE3	COMPLETED	Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
NCT00422292	PHASE3	COMPLETED	Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
NCT00432042	PHASE3	COMPLETED	Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
NCT00483574	PHASE3	COMPLETED	Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
NCT00560755	PHASE3	COMPLETED	Safety Study of ProQuad® rHA in Infants (V221-037)
NCT00566527	PHASE3	COMPLETED	Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
NCT00751348	PHASE3	COMPLETED	Immunogenicity & Safety Study of GSK Biologicals’ Combined Measles-mumps-rubella-varicella Vaccine 208136
NCT00839917	PHASE3	TERMINATED	A Study of ProQuad™ in Healthy Children in Korea (V221-023)
NCT00969436	PHASE3	COMPLETED	Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
NCT00975507	PHASE3	COMPLETED	ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
NCT00984295	PHASE3	COMPLETED	Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
NCT00985153	PHASE3	COMPLETED	Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
NCT00985166	PHASE3	COMPLETED	A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
NCT01188343	PHASE3	COMPLETED	Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
NCT01506193	PHASE3	COMPLETED	Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
NCT01536405	PHASE3	COMPLETED	Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
NCT01681992	PHASE3	COMPLETED	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RUBELLA VIRUS VACCINE LIVE	3	2